Melax Team


Innovative, Collaborative, Professional. Explore for advance clinical data analysis.

Executives



Hua Xu (CEO)

Dr. Xu is the Founder and CEO of Melax Technologies Inc. After finishing his PhD from Columbia University, he has worked as a professor of biomedical informatics at Vanderbilt University and The University of Texas Health Science Center at Houston (UTHealth), focusing on the research area of biomedical NLP.

In the past decade, he has worked on a broad range of challenging NLP topics and clinical NLP methods and systems developed in his lab have been highly recognized, e.g., top ranked in multiple competitions such as i2b2 NLP challenges, and widely applied to diverse clinical and translational research. He served as the Chair of AMIA (American Medical Informatics Association) NLP Working Group in 2013-14. Currently he leads the NLP Working Group at the OHDSI (Observational Healthcare Data Science and Informatics) consortium.

Frank Manion (VP for Innovation)

Dr. Manion has held positions in high level clinical and bioinformatics executive support roles at two major NCI-designated NCI comprehensive cancer centers. He directed research computing and bioinformatics support for the Fox Chase Cancer Center, and biomedical informatics support at the Rogel Cancer Center at the University of Michigan for 9 years.

He participated in two major NIH-funded human genome centers. At the University of Michigan, he helped develop major initiatives around scientific data representation standards and information systems interoperability architecture for the Medical School.


Others



Jingqi Wang (NLP Architect)

Jingqi Wang serves as an NLP Architect at Melax Technologies Inc, leading the NLP development team. He currently is enrolled part-time in the PhD program at School of Biomedical Informatics at The University of Health Science Center at Houston (UTHealth).

He has ten years of working experience as a software developer before he joined Melax. In the past years, he primarily worked on the development and improvement of clinical Natural Language Processing (NLP) algorithms and applications. He has contributed to multiple top-ranked systems in biomedical NLP competitions, including medical adverse event identification system in 2018 n2c2 challenge, chemical/drug recognition and chemical-induced event identification systems in 2016 Bio-CREATIVE challenge, and clinical concept extraction and normalization systems in 2014 and 2015 SemEval challenges.